About Us

We're here to transform the lives of people affected by neuromuscular disease.

Press Releases

MDA Awards Second 'Bridge-to-Industry' Grant

Submitted by jcook on Mon, 05/02/2016 - 13:21

Program Trains Researchers in Drug Development
Halo Therapeutics Receives $500,000 MDA Award to Develop Drug for Duchenne Muscular Dystrophy

Submitted by jcook on Mon, 05/02/2016 - 13:22

NEWTON, Mass., and TUCSON, Ariz., Nov. 14, 2013 — Halo Therapeutics LLC and the Muscular Dystrophy Association (MDA) today announced that $500,000 has been awarded for development of the experimental drug HT-100 as a treatment for Duchenne muscular dystrophy (DMD).
RE: FDA Says That New Drug Application Filing for Eteplirsen is Premature

Submitted by jcook on Mon, 05/02/2016 - 13:23

Background:
Press Release: Drug for Duchenne Muscular Dystrophy Successfully Completes Phase 1 Trial; Trial in Boys with DMD May Be Next

Submitted by jcook on Mon, 05/02/2016 - 13:29

MDA supported development of utrophin-boosting compounds for years

TUCSON, Ariz. — The Muscular Dystrophy Association announced today that SMT C1100, an experimental drug for Duchenne muscular dystrophy (DMD), has been found safe in healthy human volunteers and reached blood levels potentially adequate for a therapeutic benefit. Next steps are to move into trials in people with DMD.
Sarepta Therapeutics Announces Eteplirsen Demonstrates a Continued Benefit on Walking Test through 84 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy

Submitted by jcook on Mon, 05/02/2016 - 12:54

Data to be presented today at the Wells Fargo Securities 2013 Healthcare Conference
ARMGO Pharma Receives $1 Million MDA Award to Continue Development of Novel DMD Treatment

Submitted by jcook on Mon, 05/02/2016 - 13:25

TARRYTOWN, N.Y. and TUCSON, Ariz., April 17, 2013 — ARMGO Pharma and the Muscular Dystrophy Association (MDA) today announced that $1 million has been awarded for preclinical work in support of an investigational new drug (IND) application with the U.S.

Our Story

Our Team

Resources

Care Centers

Resource Center

Summer Camp

Our Approach

For Researchers

For Clinicians

Participate

Donate

Partner

About Us

Press Releases

MDA Awards Second 'Bridge-to-Industry' Grant

Program Trains Researchers in Drug Development

Halo Therapeutics Receives $500,000 MDA Award to Develop Drug for Duchenne Muscular Dystrophy

RE: FDA Says That New Drug Application Filing for Eteplirsen is Premature

Press Release: Drug for Duchenne Muscular Dystrophy Successfully Completes Phase 1 Trial; Trial in Boys with DMD May Be Next

MDA supported development of utrophin-boosting compounds for years

Sarepta Therapeutics Announces Eteplirsen Demonstrates a Continued Benefit on Walking Test through 84 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy

ARMGO Pharma Receives $1 Million MDA Award to Continue Development of Novel DMD Treatment

Find MDA
in your Community

Sign Up for MDA News & Updates

About Us

Press Releases

MDA Awards Second 'Bridge-to-Industry' Grant

Program Trains Researchers in Drug Development

Halo Therapeutics Receives $500,000 MDA Award to Develop Drug for Duchenne Muscular Dystrophy

RE: FDA Says That New Drug Application Filing for Eteplirsen is Premature

Press Release: Drug for Duchenne Muscular Dystrophy Successfully Completes Phase 1 Trial; Trial in Boys with DMD May Be Next

MDA supported development of utrophin-boosting compounds for years

Sarepta Therapeutics Announces Eteplirsen Demonstrates a Continued Benefit on Walking Test through 84 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy

ARMGO Pharma Receives $1 Million MDA Award to Continue Development of Novel DMD Treatment

Find MDA in your Community

Find MDA
in your Community